Our ref IRE/RIE/14/0003

28th May 2014

Rienso ▼ (Ferumoxytol) – On-going review of global post-marketing reports of serious hypersensitivity reactions

Dear Healthcare Professional,

In agreement with the European Medicines Agency (EMA) and Irish Medicines Board (IMB) Takeda is writing to advise you that the EMA is currently reviewing new global post-marketing data for Rienso relating to serious hypersensitivity reactions. Whilst the review is on-going the attention of healthcare professionals is being drawn to the existing risk minimisation measures for all intravenous iron products, including Rienso as set out in the product information, to manage and minimise the risk of serious hypersensitivity reactions.

Summary:

- **Rienso is contraindicated in patients with known hypersensitivity to the active substance or any of its excipients.**
- **Rienso is contraindicated in patients with known serious hypersensitivity to other parenteral iron products.**
- **The risk of hypersensitivity is increased in patients with known allergies (including drug allergies), in patients with immune or inflammatory conditions (e.g. systemic lupus erythematosus, rheumatoid arthritis) as well as in patients with a history of severe asthma, eczema or other atopic allergy. In these patients, Rienso should only be used if the benefit is clearly judged to outweigh the potential risk.**
- **Rienso should only be administered when staff trained to evaluate and manage anaphylactic reactions as well as resuscitation facilities are immediately available.**
- **Patients should be closely monitored for signs of hypersensitivity, including severe hypotension, during and for at least 30 minutes after each administration of Rienso.**
- **Before each administration patients should be informed of the risk of hypersensitivity. Patients should also be informed of the relevant symptoms and asked to seek urgent medical attention if a reaction occurs.**

Further information on the safety concern

Parenterally administered iron preparations are known to cause hypersensitivity reactions including serious and potentially fatal anaphylactic reactions. Hypersensitivity reactions have also been reported after previously uneventful doses of parenteral iron complexes.

Takeda UK Ltd.
Takeda House, Mercury Park, Wycombe Lane, Wooburn Green, High Wycombe, Buckinghamshire HP10 0HH United Kingdom
Tel: +44(0) 1628 537900 • Fax: +44(0) 1628 526615 • www.takeda.co.uk

Rienso was approved in the European Union in June 2012 for the intravenous treatment of iron deficiency anaemia in adult patients with chronic kidney disease (CKD) and was therefore not included in the review by the European Medicines Agency of all other parenteral iron containing products which started in December 2011. However Takeda have aligned Rienso's Product Information with that of all the other IV irons as communicated in the previous Direct Healthcare Professional Communication ('DHPC') letter distributed January 2014.

Serious hypersensitivity reactions including anaphylactic reactions, some of which have been life-threatening or fatal, have been reported in patients receiving Rienso. The majority of these reports are from the United States of America where the product has been available since 2009. The benefits and risks of Rienso are currently being evaluated in the context of a regular procedure known as Periodic Safety Update Report (PSUR). A PSUR is intended to reevaluate the benefit risk ratio of a medicinal product at defined time points post-authorisation. This reminder of the current recommendations to manage and minimise the risk of serious hypersensitivity reactions included in the current product information for Rienso is given whilst the finalisation of the assessment is awaited.

Should you have any questions regarding the use of Rienso or questions about the content of this letter, please contact your local Takeda affiliate or representative (see contact details below under Contact point).

Yours sincerely,

Kieran Leahy
General Manager
Takeda Products Ireland Ltd
First floor, 3013 Lake Drive,
Citywest Business Campus,
Dublin 24,
Republic of Ireland
Tel: 0862 805132
Email: Kieran.leahy@takeda.com

Call for reporting

Any suspected adverse events should be reported to the National Spontaneous Reporting System according to the National Regulation.

This is accessible via the IMB homepage (www.imb.ie). A downloadable form is also accessible from the IMB website, which may be completed manually and submitted to the IMB via 'freepost' (address below). Alternatively, the traditional post-paid 'yellow card' option may also be used.

FREEPOST: Pharmacovigilance Section, Irish Medicines Board, Kevin O'Malley House, Earlsfort Centre, Earlsfort Terrace, Dublin 2, Ireland. Tel: +353 1 6764971, Fax: +353 1 6767836, Website: www.imb.ie Email: imbpharmacovigilance@imb.ie.

Company contact point

If you have any further questions please contact Takeda UK Ltd:

Takeda UK Ltd, Mercury Park, Wycombe Lane, Wooburn Green, High Wycombe, HP10 0HH. Tel: 1800 937 970, Fax: +44 1628 526617, Email: DSO-UK@takeda.com, Website: www.takeda.co.uk